Autoantibodies in systemic lupus erythematosus and normal subjects

1986 ◽  
Vol 5 (3) ◽  
pp. 338-345 ◽  
Author(s):  
E. Pateraki ◽  
E. Kaklamani ◽  
Ph. Kaklamanis ◽  
R. Portocalas ◽  
A. Aessopos
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Normal Subjects ◽  
Systemic Lupus

scholarly journals Diet in Rheumatoid Arthritis versus Systemic Lupus Erythematosus: Any Differences?

Nutrients ◽  
2021 ◽  
Vol 13 (3) ◽  
pp. 772
Author(s):  
Alessia Alunno ◽  
Francesco Carubbi ◽  
Elena Bartoloni ◽  
Davide Grassi ◽  
Claudio Ferri ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Musculoskeletal Diseases ◽  
Normal Subjects ◽  
Experimental Models ◽  
Systemic Lupus ◽  
History Of ◽  
Indirect Action

In recent years, an increasing interest in the influence of diet in rheumatic and musculoskeletal diseases (RMDs) led to the publication of several articles exploring the role of food/nutrients in both the risk of developing these conditions in normal subjects and the natural history of the disease in patients with established RMDs. Diet may be a possible facilitator of RMDs due to both the direct pro-inflammatory properties of some nutrients and the indirect action on insulin resistance, obesity and associated co-morbidities. A consistent body of research has been conducted in rheumatoid arthritis (RA), while studies in systemic lupus erythematosus (SLE) are scarce and have been conducted mainly on experimental models of the disease. This review article aims to outline similarities and differences between RA and SLE based on the existing literature.

PRESENCE OF THE LUPUS ANTICOAGULANT IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS DOES NOT CAUSE INHIBITION OF PROSTACYCLIN PRODUCTION

1987 ◽  
Author(s):  
M H A Rustin ◽  
H A Bull ◽  
P M Dowd ◽  
D A Isenberg ◽  
M L Snaith ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Lupus Anticoagulant ◽  
Umbilical Vein ◽  
Normal Subjects ◽  
Ionophore A23187 ◽  
Systemic Lupus ◽  
Dependent Inhibition ◽  
Prostacyclin Production ◽  
Thrombotic Tendency

The cause of the thrombotic tendency in patients having the lupus anticoagulant (LA) is unknown. Since inhibition of prostacyclin production by endothelial cells (EC) may be a pathogenetic factor, the effect of sera from normal subjects (NS, n=9), SLE (systemic lupus erythematosus) + LA (n=9) and SLE-LA (n=13) on the production of PGI2 by cultured human EC was studied.Confluent 1° cultures of human umbilical vein EC were incubated with 1, 5, 10 and 20% sera from the above for 24 hours. After stimulation with thecalcium ionophore A23187, 6-keto-PGF1α(the stable metabolite of PGI2) in the supernatant was measured by radioimmunoassay.A dose dependent inhibition of 6-keto-PGF1α was observed with all the sera but only the 10 and 20% sera from patients with SLE-LA produced a significantly greater inhibition than control sera. The mean production of 6-keto-PGFia (ng/104 cells) was 2.278 (NS), 2.6594 (SLE-LA) and 2.1418 (SLE + LA)after incubation with 1% sera for 24 hours. This decreased to 1.3647, 0.6517 and 0.942 respectively following incubation with 20% sera. This represented a 44% (NS), 71% (SLE-LA) and 62% (SLE + LA) inhibition of 6-keto-PGF1α production compared to serum free media.The non-significant reduction in prostacyclin production by sera from patients with SLE and the lupus anticoagulant suggests that other factors are responsible for the thrombotic tendency in these patients.

The Different Immunomodulation of Indirect Moxibustion on Normal Subjects and Patients with Systemic Lupus Erythematosus

2006 ◽  
Vol 34 (01) ◽  
pp. 47-56 ◽  
Author(s):  
Yen-Ying Kung ◽  
Fang-Pey Chen ◽  
Shinn-Jang Hwang
Keyword(s):  
Systemic Lupus Erythematosus ◽  
T Lymphocytes ◽  
Lupus Erythematosus ◽  
Disease Status ◽  
Normal Subjects ◽  
Indirect Moxibustion ◽  
Acupuncture Points ◽  
Immunomodulatory Effects ◽  
Systemic Lupus ◽  
Abnormal Immune Response

Moxibustion has been thought to enhance immunity in healthy condition, but suppress abnormal immune response in disease status. We collected 12 patients with systemic lupus erythematosus (SLE) and 12 healthy women who received indirect moxibustion on acupuncture points ST-36 (Zusanli) and SP-6 (Sanyinjiao) 20 minutes per day for 1 week. During the course, there were no changes of their regular medications or intercurrent infections in normal subjects and SLE patients. We found that indirect moxibustion for 1 week could elevate CD3+ and CD4+ T-lymphocytes in normal subjects, whereas decrease relative proportions of CD8+ T-lymphocytes in patients with SLE. This result confirms that indirect moxibustion has different immunomodulation in normal condition and autoimmune status. However, whether immunomodulatory effects of indirect moxibustion are beneficial for normal subjects and patients with SLE require further confirmation.

scholarly journals Phenotyping of P105-Negative B Cell Subsets in Patients with Systemic Lupus Erythematosus

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Syuichi Koarada ◽  
Yoshifumi Tada ◽  
Rie Suematsu ◽  
Sachiko Soejima ◽  
Hisako Inoue ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Flow Cytometry ◽  
B Cells ◽  
B Cell ◽  
Lupus Erythematosus ◽  
Normal Subjects ◽  
Systemic Lupus ◽  
Phenotypic Analysis ◽  
B Cell Subsets

This study aimed to investigate phenotype of RP105(−) B cell subsets in patients with systemic lupus erythematosus (SLE). Flow cytometry was used for phenotyping RP105-negaive B cell subsets. Based on CD19, RP105, and CD138 expression, RP105(−) B cells consist of at least 5 subsets of late B cells, including CD19(+)RP105(int), CD19(+) RP105(−), CD19(low) RP105(−) CD138(−), CD19(low) RP105(−)CD138(int), and CD19(low) RP105(−) CD138(++) B cells. Especially, CD19(+)RP105(int) and CD19(low) RP105(−)CD138(int) B cells are significantly larger than other RP105(−) B cell subsets in SLE. By comparison of RP105(−) B cell subsets between patients with SLE and normal subjects, these subsets were detectable even in normal subjects, but the percentages of RP105(−) B cell subsets were significantly larger in SLE. The phenotypic analysis of RP105(−) B cell subsets suggests dysregulation of later B cell subsets in SLE and may provide new insights into understanding regulation of B cells in human SLE.

scholarly journals Variable Increased Expression of Program Death-1 and Program Death-1 Ligands on Peripheral Mononuclear Cells Is Not Impaired in Patients with Systemic Lupus Erythematosus

2009 ◽  
Vol 2009 ◽  
pp. 1-6 ◽  
Author(s):  
Ming-Fei Liu ◽  
Chia-Tse Weng ◽  
Meng-Yu Weng
Keyword(s):  
Systemic Lupus Erythematosus ◽  
T Cells ◽  
B Cells ◽  
Lupus Erythematosus ◽  
Mononuclear Cells ◽  
Normal Subjects ◽  
Functional Study ◽  
Systemic Lupus ◽  
Circulating T Cells ◽  
And Function

Programmed death-1 (PD-1) was shown to deliver an inhibitory signal after binding to its ligands, PD-L1 (B7-H1) or PD-L2 (B7-DC). Recently, up-regulated expression of PD-1 molecule and/or its ligands was demonstrated in human diseases including rheumatoid arthritis and inflammatory colitis. The study aimed to investigate the expression and function of PD-1 and PD-1 ligands on circulating T cells, B cells and monocytes from patient with systemic lupus erythematosus (SLE). The results showed that patients with SLE had significantly increased percentages of PD-1-expressing CD3+T cells and CD19+B cells, PD-L1-expressing CD19+B cells and PD-L2-expressing CD14+B monocytes. In selected SLE patients and normal subjects, functional study of PD-1/ PD-1 ligands pathway on the production of cytokines by stimulated PBMC was examined. Blockages of PD-1 or PD-1 ligands substantially increased the production of IL-2, IFN-γand IL-10, the amplitude of increase roughly ranged from one to three times. There were no significant differences of the enhancing effects on cytokine production by blockage of PD-1/PDL pathway between SLE patients and normal subjects. The study indicates that there are no intrinsically defective expression and function of PD-1 and PD-1 ligands on PBMC in patients with SLE.

scholarly journals Migraine In Systemic Lupus Erythematosus in Rheumatological outpatients unit

2019 ◽  
Vol 13 (1) ◽  
pp. 51-55
Author(s):  
Ameer Shaker
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Lupus Erythematosus ◽  
Raynaud’S Phenomenon ◽  
Normal Subjects ◽  
Raynaud's Phenomenon ◽  
Cross Sectional Study ◽  
High Rate ◽  
Systemic Lupus ◽  
Cross Sectional ◽  
Cardiolipin Antibodies

Background: Migraine is common in systemic lupus erythematosus.It is a significant source of patient disability. Objective: To determine the rate of migraine in patients with systemic lupus erythematosus, to assess migraine type, severity, and the association between migraine and patient’s characteristics. Type of the study: Cross-sectional study. Methods: 100 subjected were recruited and divided into two groups; fifty patients with the diagnosis of systemic lupus erythematosus were recruited from the Rheumatologic department of medicine,and another 50 normal subjects, then complete medical and drugs history were taken from them. Results: Fifty patients completed the questionnaire. Thirty percent of systemic lupus erythematosus patients and 12% of normal subjects had migraine. Of the patients with migraine 80%, 13.3% and 6.7% met criteria for migraine without aura, migraine with aura and retinal migraine respectively. The moderately severe migraine was commonly observed (53.3%). There were significant associations between migraine and systemic lupus erythematosus patients who have Raynaud’s phenomenon, and cardiolipin antibodies.There were no statistically significant associations between migraine, systemic lupus erythematosus duration and patient’s age,sex, and anti-dsDNA. Conclusions:A high rate of migraine in patients with systemic lupus erythematosus.Migraine associated with Raynaud’s phenomenon, and cardiolipin antibodies.

Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls

2007 ◽  
Vol 67 (4) ◽  
pp. 450-457 ◽  
Author(s):  
A M Jacobi ◽  
D M Goldenberg ◽  
F Hiepe ◽  
A Radbruch ◽  
G R Burmester ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
B Cells ◽  
B Cell ◽  
Lupus Erythematosus ◽  
Peripheral Blood ◽  
Therapeutic Option ◽  
Normal Subjects ◽  
Systemic Lupus

Objective:B lymphocytes have been implicated in the pathogenesis of lupus and other autoimmune diseases, resulting in the introduction of B cell-directed therapies. Epratuzumab, a humanised anti-CD22 monoclonal antibody, is currently in clinical trials, although its effects on patients’ B cells are not completely understood.Methods:This study analysed the in vivo effect of epratuzumab on peripheral B cell subsets in 12 patients with systemic lupus erythematosus, and also addressed the in vitro effects of the drug by analysing anti-immunoglobulin-induced proliferation of isolated B cells obtained from the peripheral blood of 11 additional patients with lupus and seven normal subjects.Results:Upon treatment, a pronounced reduction of CD27– B cells and CD22 surface expression on CD27– B cells was observed, suggesting that these cells, which mainly comprise naïve and transitional B cells, are preferentially targeted by epratuzumab in vivo. The results of in vitro studies indicate additional regulatory effects of the drug by reducing the enhanced activation and proliferation of anti-immunoglobulin-stimulated lupus B cells after co-incubation with CD40L or CpG. Epratuzumab inhibited the proliferation of B cells from patients with systemic lupus erythematosus but not normal B cells under all culture conditions.Conclusions:Epratuzumab preferentially modulates the exaggerated activation and proliferation of B cells from patients with lupus in contrast to normal subjects, thus suggesting that epratuzumab might offer a new therapeutic option for patients with systemic lupus erythematosus, as enhanced B cell activation is a hallmark of this disease.

Sign in / Sign up

Export Citation Format

Share Document